Cilostazol Capsules

This product inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by endothelial cells. For patients with chronic arterial occlusion, the use of volume volumography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and skin temperature of the limbs, and improve intermittent claudication.

The main ingredient is cilostazol.

This product is a hard capsule, and the contents are white granular powder.

The medicine is used to improve ischemic symptoms such as ulcers, limb pain, coldness and intermittent claudication caused by chronic arterial occlusive disease.

Oral: Adults, 50-100 mg at a time, twice a day. For young patients, the dose can be increased appropriately if necessary based on symptoms.

1. The main adverse reactions are headache, dizziness and palpitations caused by vasodilation, and some patients may have high blood pressure; 2. The second most common adverse reactions are digestive tract symptoms such as abdominal distension, nausea, vomiting, stomach discomfort, abdominal pain, etc.; 3. A small number of patients developed abnormal liver function, frequent urination, abnormal urea nitrogen, creatinine and uric acid levels after taking the medicine; 4. Allergic symptoms include rash and itching; 5. There have been occasional reports of leukopenia, subcutaneous hemorrhage, gastrointestinal bleeding, epistaxis, hematuria, fundus hemorrhage, etc.

Patients with bleeding disorders (such as hemophilia, capillary fragility, active peptic ulcer, hematuria, hemoptysis, functional uterine bleeding, etc. or other bleeding tendencies).

Precautions for children: The safety of children's use has not been established. Precautions for pregnancy and lactation: Pregnant and lactating women or women who are planning/may become pregnant are prohibited. Precautions for the elderly: No such test has been conducted and there is no reliable reference document.

Prostaglandin E1 can act synergistically with this product to increase intracellular cyclic adenosine monophosphate and enhance therapeutic efficacy.

Keep away from light and store in a sealed place.

50 mg

18 months

Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.

• Founded in:

  1998-12-30

• Address:

  South side of Dongshan, Jinshanqiao Development Zone, Xuzhou City, Jiangsu Province

• Tax NO.:

  91320300714139872F

• Registered Funds:

  480.4554 million yuan

• Website:

  Log in to view

• Email:

  Log in to view